Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the

E J Shannon1, M Ejigu, H S Haile-Mariam

  • 1Pharmacology Research Department, G.W. Long Hansen's Disease Center, Carville, La 70721.

Leprosy Review
|March 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thalidomide inhibited the synthesis of IgM and IgG whereas Thalidomide+Dexamethasone and Dexamethasone alone acted as co-stimulants with pokeweed and enhanced their synthesis.

International immunopharmacology·2010
Same author

A geospatial risk assessment model for leprosy in Ethiopia based on environmental thermal-hydrological regime analysis.

Geospatial health·2008
Same author

Thalidomide and thalidomide transformed by pH-dependent hydrolysis or by liver enzyme treatment does Not impede the proliferation of endothelial cells.

Immunopharmacology and immunotoxicology·2008
Same author

Effect of thalidomide on the expression of TNF-alpha m-RNA and synthesis of TNF-alpha in cells from leprosy patients with reversal reaction.

Immunopharmacology and immunotoxicology·2006
Same author

Concerns regarding in vitro and in vivo uses of thalidomide.

Leprosy review·2005
Same author

Stabilization of red blood cell membranes by thalidomide in vitro.

Immunopharmacology and immunotoxicology·2005

Thalidomide effectively treats erythema nodosum leprosum (ENL) by reducing CD4+ lymphocytes. This study observed thalidomide

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Erythema nodosum leprosum (ENL) is a complication of leprosy.
  • The pathogenesis of ENL and thalidomide's mechanism of action are not fully understood.
  • Lepromatous leprosy patients with ENL exhibit an elevated CD4+ to CD8+ lymphocyte ratio.

Purpose of the Study:

  • To investigate the association between thalidomide treatment and lymphocyte subset changes in patients with chronic ENL.
  • To explore thalidomide's effect on the CD4+ to CD8+ lymphocyte ratio in the context of ENL management.

Main Methods:

  • Case study involving two male lepromatous leprosy patients with chronic ENL.
  • Monitoring of CD4+ and CD8+ lymphocyte counts in peripheral blood during thalidomide therapy.

Related Experiment Videos

  • Clinical assessment of ENL activity and relapse status.

    • Main Results:

    • Thalidomide treatment was associated with a decrease in CD4+ lymphocyte counts.
    • The reduction in CD4+ lymphocytes correlated with the halting of chronic ENL and prevention of relapse.
    • Observed changes in lymphocyte subsets support thalidomide's therapeutic effect in ENL.

    Conclusions:

    • Thalidomide's efficacy in managing ENL is linked to a modulation of the CD4+ lymphocyte population.
    • Further research is warranted to elucidate the precise immunomodulatory mechanisms of thalidomide in ENL.
    • Findings suggest a potential biomarker role for CD4+ lymphocyte levels in thalidomide-treated ENL patients.